UPMC has been selected as a center for the GALACTIC Study, a double-blind, randomized, placebo-controlled, multicenter study to assess the efficacy and safety of omecamtiv mecarbil on mortality and morbidity in subjects with chronic heart failure with reduced ejection fraction

We are currently enrolling men and women who have been diagnosed with heart failure with a reduced ejection fraction. The primary purpose of this study is to evaluate the effectiveness of the study drug, omecamtiv mecarbil, compared to placebo plus background standard-of-care therapy, to time of cardiovascular death or first heart failure exacerbation.

Omecamtiv mecarbil acts as a cardiac myosin activator, targeting the myocardial contractility. It is shown to reduce LV filling pressures and total peripheral vascular resistance.

Which patients are eligible?

Potential candidates for GALACTIC must meet the following primary inclusion criteria:

  • Diagnosis of chronic heart failure with an EF of <35 percent
  • NYHA Class II-IV
  • Between the ages of 18 and 85
  • Current hospitalization for heart failure exacerbation or had an admission within the past 12 months prior to screening with the primary reason of heart failure
  • BNP ­> 125 pg/mL (iff in Afib/flutter at screening: ≥ 375)

Contact us

For a full list of inclusion/exclusion criteria or to refer a patient:

Marc Simon, MD, is the principal investigator at UPMC.  If you know a patient you believe may qualify, please call Mary Kunkel, RN, BSN, research nurse coordinator at 412-647-4463 or email